XOMA Quote, Financials, Valuation and Earnings

Recursion Pharmaceuticals, Inc. has a net margin of 52.48% compared to XOMA Royalty Corp.'s net margin of -3135.32%. XOMA Royalty Corp.'s return on equity of 17.31% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

XOMA Royalty Corp. has a consensus price target of $64.50, signalling upside risk potential of 144.6%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 49.89%. Given that XOMA Royalty Corp. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe XOMA Royalty Corp. is more attractive than Recursion Pharmaceuticals, Inc..

XOMA Royalty Corp. has a beta of 0.889, which suggesting that the stock is 11.101% less volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

XOMA Royalty Corp. has a quarterly dividend of $0.54 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XOMA Royalty Corp. pays 39.59% of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

XOMA Royalty Corp. quarterly revenues are $9.4M, which are larger than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. XOMA Royalty Corp.'s net income of $10.3M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, XOMA Royalty Corp.'s price-to-earnings ratio is 35.37x while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XOMA Royalty Corp. is 9.17x versus 42.84x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rezolute, Inc. has a net margin of 52.48% compared to XOMA Royalty Corp.'s net margin of --. XOMA Royalty Corp.'s return on equity of 17.31% beat Rezolute, Inc.'s return on equity of -63.8%.

XOMA Royalty Corp. has a consensus price target of $64.50, signalling upside risk potential of 144.6%. On the other hand Rezolute, Inc. has an analysts' consensus of $4.25 which suggests that it could grow by 55.68%. Given that XOMA Royalty Corp. has higher upside potential than Rezolute, Inc., analysts believe XOMA Royalty Corp. is more attractive than Rezolute, Inc..

XOMA Royalty Corp. has a beta of 0.889, which suggesting that the stock is 11.101% less volatile than S&P 500. In comparison Rezolute, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 61.035%.

XOMA Royalty Corp. has a quarterly dividend of $0.54 per share corresponding to a yield of 0%. Rezolute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XOMA Royalty Corp. pays 39.59% of its earnings as a dividend. Rezolute, Inc. pays out -- of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

XOMA Royalty Corp. quarterly revenues are $9.4M, which are larger than Rezolute, Inc. quarterly revenues of --. XOMA Royalty Corp.'s net income of $10.3M is higher than Rezolute, Inc.'s net income of -$18.2M. Notably, XOMA Royalty Corp.'s price-to-earnings ratio is 35.37x while Rezolute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XOMA Royalty Corp. is 9.17x versus -- for Rezolute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vistagen Therapeutics, Inc. has a net margin of 52.48% compared to XOMA Royalty Corp.'s net margin of -7525.97%. XOMA Royalty Corp.'s return on equity of 17.31% beat Vistagen Therapeutics, Inc.'s return on equity of -76.57%.

XOMA Royalty Corp. has a consensus price target of $64.50, signalling upside risk potential of 144.6%. On the other hand Vistagen Therapeutics, Inc. has an analysts' consensus of $0.97 which suggests that it could grow by 45.63%. Given that XOMA Royalty Corp. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe XOMA Royalty Corp. is more attractive than Vistagen Therapeutics, Inc..

XOMA Royalty Corp. has a beta of 0.889, which suggesting that the stock is 11.101% less volatile than S&P 500. In comparison Vistagen Therapeutics, Inc. has a beta of 0.307, suggesting its less volatile than the S&P 500 by 69.277%.

XOMA Royalty Corp. has a quarterly dividend of $0.54 per share corresponding to a yield of 0%. Vistagen Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XOMA Royalty Corp. pays 39.59% of its earnings as a dividend. Vistagen Therapeutics, Inc. pays out -- of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

XOMA Royalty Corp. quarterly revenues are $9.4M, which are larger than Vistagen Therapeutics, Inc. quarterly revenues of $258K. XOMA Royalty Corp.'s net income of $10.3M is higher than Vistagen Therapeutics, Inc.'s net income of -$19.4M. Notably, XOMA Royalty Corp.'s price-to-earnings ratio is 35.37x while Vistagen Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XOMA Royalty Corp. is 9.17x versus 23.30x for Vistagen Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics, Inc. has a net margin of 52.48% compared to XOMA Royalty Corp.'s net margin of -2.09%. XOMA Royalty Corp.'s return on equity of 17.31% beat Zevra Therapeutics, Inc.'s return on equity of 44.06%.

XOMA Royalty Corp. has a consensus price target of $64.50, signalling upside risk potential of 144.6%. On the other hand Zevra Therapeutics, Inc. has an analysts' consensus of $22.54 which suggests that it could grow by 152.45%. Given that Zevra Therapeutics, Inc. has higher upside potential than XOMA Royalty Corp., analysts believe Zevra Therapeutics, Inc. is more attractive than XOMA Royalty Corp..

XOMA Royalty Corp. has a beta of 0.889, which suggesting that the stock is 11.101% less volatile than S&P 500. In comparison Zevra Therapeutics, Inc. has a beta of 1.080, suggesting its more volatile than the S&P 500 by 8.038%.

XOMA Royalty Corp. has a quarterly dividend of $0.54 per share corresponding to a yield of 0%. Zevra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XOMA Royalty Corp. pays 39.59% of its earnings as a dividend. Zevra Therapeutics, Inc. pays out -- of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

XOMA Royalty Corp. quarterly revenues are $9.4M, which are smaller than Zevra Therapeutics, Inc. quarterly revenues of $26.1M. XOMA Royalty Corp.'s net income of $10.3M is higher than Zevra Therapeutics, Inc.'s net income of -$544K. Notably, XOMA Royalty Corp.'s price-to-earnings ratio is 35.37x while Zevra Therapeutics, Inc.'s PE ratio is 14.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XOMA Royalty Corp. is 9.17x versus 5.78x for Zevra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.